Clinical Research

DSPA is developing innovative investigational medicines with novel mechanisms of action, intended to significantly improve treatment options for patients in a variety of therapeutic areas including schizophrenia, diabetes, and inflammation/allergy. To learn more about our global pipeline click here.

The Company has significant expertise in developing treatments for various CNS disorders, including schizophrenia, anxiety disorder, epilepsy, and Parkinson’s disease.

With the development of our late-stage candidate for the treatment of schizophrenia, We aim to extend our experience, commitment, and vision worldwide.

To learn more about ongoing clinical trials, please visit www.clinicaltrials.gov